Search Within

Igor Odintsov

  1. "Thoracic Oncology"
Formats
  1. Journal Article (8)
  2. Editorial (1)
  3. Meeting Abstract (1)
Groups
  1. Department of Medicine (10)
  2. Department of Pathology and Laboratory Medicine (10)
  3. GSK Faculty (10)
  4. Human Oncology and Pathogenesis Program (10)
  5. Sloan Kettering Institute Postdocs (10)
  6. Solid Tumor Oncology Division (10)

More Groups

People
  1. Marc Ladanyi (10)
  2. Romel Somwar (10)
  3. Alexander Drilon (8)
  4. Elisa De Stanchina (7)
  5. Gregory Riely (5)
  6. Inna Khodos (5)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2022 (2)
  4. 2021 (4)
  5. 2020 (1)
  6. 2019 (1)
Publications
  1. JCO Precision Oncology (2)
  2. Journal of Thoracic Oncology (2)
  3. Cancer Discovery (1)
  4. Cancer Research (1)
  5. Communications Biology (1)
  6. Disease Models & Mechanisms (1)

More Publications

Publishers
  1. American Association for Cancer Research (3)
  2. American Society of Clinical Oncology (3)
  3. Elsevier Inc. (2)
  4. Company of Biologists (1)
  5. Springer Nature (1)

Results (10)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Combination of MDM2 and targeted kinase inhibitors results in prolonged tumor control in lung adenocarcinomas with oncogenic tyrosine kinase drivers and MDM2 amplification
    Journal Article

    Elkrief, A.; Odintsov, I.; Smith, R. S.; Vojnic, M.; Hayashi, T.; Khodos, I.; Markov, V.; Liu, Z.; Lui, A. J. W.; Bloom, J. L.; more...
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save
  • Combination therapy with MDM2 and MEK inhibitors is effective in patient-derived models of lung adenocarcinoma with concurrent oncogenic drivers and MDM2 amplification
    Journal Article

    Elkrief, A.; Odintsov, I.; Markov, V.; Caeser, R.; Sobczuk, P.; Tischfield, S. E.; Bhanot, U.; Vanderbilt, C. M.; Cheng, E. H.; Drilon, A.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Zenocutuzumab, a HER2XHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements
    Journal Article

    Schram, A. M.; Odintsov, I.; Espinosa-Cotton, M.; Khodos, I.; Sisso, W. J.; Mattar, M. S.; Lui, A. J. W.; Vojnic, M.; Shameem, S. H.; Chauhan, T.; more...
    Cancer Discovery (2022)

    Fulltext@MSK | Save
  • MYC promotes tyrosine kinase inhibitor resistance in ROS1-fusion-positive lung cancer
    Journal Article

    Iyer, S. R.; Odintsov, I.; Schoenfeld, A. J.; Siau, E.; Mattar, M. S.; de Stanchina, E.; Khodos, I.; Drilon, A.; Riely, G. J.; Ladanyi, M.; more...
    Molecular Cancer Research (2022)

    Fulltext@MSK | Save
  • MYC promotes tyrosine kinase inhibitor resistance in ROS1 fusion positive lung cancers
    Meeting Abstract

    Iyer, S. R.; Odintsov, I.; Schoenfeld, A. J.; Sato, H.; Siau, E.; Drilon, A.; Riely, G. J.; Somwar, R.; Ladanyi, M.; Davare, M. A.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers
    Journal Article

    Odintsov, I.; Mattar, M. S.; Lui, A. J. W.; Offin, M.; Kurzatkowski, C.; Delasos, L.; Khodos, I.; Asher, M.; Daly, R. M.; Rekhtman, N.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • RET inhibition in novel patient-derived models of RET fusion-positive lung adenocarcinoma reveals a role for MYC upregulation
    Journal Article

    Hayashi, T.; Odintsov, I.; Smith, R. S.; Ishizawa, K.; Liu, A. J. W.; Delasos, L.; Kurzatkowski, C.; Tai, H.; Gladstone, E.; Vojnic, M.; more...
    Disease Models & Mechanisms (2021)

    Fulltext@MSK | Save
  • ROS1 at the crossroads of clinical oncology, molecular diagnostics, and drug development
    Editorial

    Odintsov, I.; Somwar, R.; Ladanyi, M.; Drilon, A.
    JCO Oncology Practice (2021)

    Fulltext@MSK | Save
  • NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
    Journal Article

    Somwar, R.; Hofmann, N. E.; Smith, B.; Odintsov, I.; Vojnic, M.; Linkov, I.; Tam, A.; Khodos, I.; Mattar, M. S.; de Stanchina, E.; more...
    Communications Biology (2020)

    Fulltext@MSK | Save
  • Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer
    Journal Article

    Suzawa, K.; Offin, M.; Schoenfeld, A. J.; Plodkowski, A. J.; Odintsov, I.; Lu, D.; Lockwood, W. W.; Arcila, M. E.; Rudin, C. M.; Drilon, A.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save